You are currently viewing our desktop site, do you want to download our app instead?
Moneyweb Android App Moneyweb iOS App Moneyweb Mobile Web App

Vaccine production in South Africa

How an industry in its infancy can be developed.
South Africa does not have large-scale vaccine manufacturing capability. Image: Shutterstock

The issue of vaccine production has become a topic of hot debate following the approval of treatments for Covid-19. In South Africa angry exchanges have been spurred by the country’s lagging access to Covid-19 vaccines.

Generally, vaccines are produced by private companies who sell the vaccine under contracts. In some cases, producers will make provisions for access in particular markets. This is sometimes as a condition for receiving early development funding or for allowing parts of production to occur in a particular country. Some middle-income countries, particularly India, Argentina and Mexico, have sufficient production capacity to be partly indispensable. These countries have strategic leverage to get vaccines because of their own vaccine manufacturing capacity.

India illustrates this well. The Serum Institute of India, a privately owned pharmaceutical company, is manufacturing large quantities of the University of Oxford/AstraZeneca and Novavax Covid-19 vaccines. The company scheduled to reach 100 million doses produced a month by March 2021. In return, India will keep a portion of the vaccines it manufactures – reportedly 100 million doses in the first instance.
What about South Africa’s own capacity to produce vaccines? What can the country do?

South Africa does not have large-scale vaccine manufacturing capability. The Biovac Institute – a public-private partnership between the South African government and a consortium of South African healthcare companies – is beginning to get into vaccine manufacture with an eye on more secure and accessible childhood vaccine supplies for southern Africa. But this capability is still in its infancy. It’s small compared to the Covid-19 vaccine market.

In addition, a publicly traded South African-owned global pharmaceutical company, Aspen Pharmaceuticals operates four pharmaceutical manufacturing and packaging plants in the country. The company is also moving into the vaccine packaging market.

We see a clear disconnect between what would be needed to make the Biovac Institute a strategic vaccine asset going forward and what is planned for Biovac.

If South Africa is serious about supplying anti-pandemic vaccines in the future, it needs to rethink the scale of financial, technical and strategic investment into vaccine production. This investment must be made not only into the private sector, but also, critically, into publicly accountable institutions such as the Biovac Institute. Only if investment is increased, sustained, and backed by political commitment, will the country have sufficient vaccine production capacity to use as a lever to get national and regional access to future anti-pandemic vaccines.

Vaccine production capacity

The Biovac Institute’s primary remit is to make childhood vaccines available for the southern African market, mostly for the public sector.

For its part, Aspen’s existing pharmaceutical manufacturing capacity is about 10 billion tablets a year. It produces generic drugs (including analgesics, a proton pump inhibitor and sleeping aids), nutritional supplements (notably iron supplements) and hormones for local African markets and other middle income markets, such as Turkey.

Aspen is scheduled to start producing the Johnson & Johnson Covid-19 vaccine in March or April of 2021 at these facilities. It will be filling and packaging vials with vaccine product manufactured in bulk outside of South Africa.

Most of the vials will be shipped back to Johnson & Johnson for international distribution. A recent announcement indicates that 9 million doses will remain in South Africa for local use. The original packaging deal between Aspen and Johnson & Johnson was announced more than two months prior. There had been no mention of a procurement deal for South Africa until pressure began to mount recently on all parties.

Unlike Aspen, Biovac’s remit is to provide vaccines in the public interest. Part of its mission is

to provide in the long term, capacity for the development and introduction of novel vaccines, focusing on the development of vaccines relevant to South Africa and Africa’s particular needs.

Biovac’s main activity is to import, label and distribute vaccines to the South African market. For example, it has supplied six vaccines made by international vaccine manufacturers for South Africa’s childhood immunisation programme. It also supplies other countries in the region.

Biovac’s crowning achievement has been the local production (filling and packaging) of Hexaxim, a combination of six childhood vaccines from Sanofi, the French multinational pharmaceutical company. Production started very recently, in November 2020.

Biovac is the first external company with which Sanofi has partnered to fill and package Hexaxim.

Biovac is also planning to manufacture Prevnar-13, a vaccine made by Pfizer, the US multinational pharmaceutical company. The vaccine prevents pneumococcal disease and death. Biovac will formulate the product using components provided by Pfizer before filling and packaging the bulk vaccine. Production is due to start in the next six months.

The development of local capacity for formulation of a complex vaccine marks another important step towards the establishment of vaccine manufacturing capacity in South Africa.

How to be more prepared next time

To be in a better position to procure anti-pandemic vaccines South Africa will need to have greater vaccine manufacturing capacity. And the country would need to be more willing to use that capacity as leverage.

Scale is a key consideration. Biovac is planning to fill 4 million doses of hexaxim in 2021. This is tiny compared to Serum Institute of India’s huge capacity and to Aspen’s reported capacity of 300 million vaccine doses a year.

Beyond scale, two other conditions need to be met.

The first is simply more experience. The technology transfer for each vaccine that Biovac produces would give the company experience and technical capacity in re-tooling for formulation, filling and testing of each particular vaccine. The second is that a more savvy entrepreneurial risk-taking environment needs to be developed. This needs to be backed by political commitment in government.

The Aspen example shows that the development of local manufacturing capacity is possible if enough capital is available, and if the right strategic partnerships are established. Private facilities like Aspen clearly can become leverage for local access; but, that does not seem to well assured.

If Biovac’s current trajectory is maintained and supported, it should be able to supply other vaccines (childhood vaccines, mostly) in the future. The strategic value of this assured supply should not be underestimated.

In addition, Biovac could be one of the answers to this problem because it is a publicly accountable institution and because it can point to its remit to make vaccines accessible locally when making any production deals. But in its current incarnation and scale, Biovac won’t be able to provide anti-pandemic vaccines for southern Africa. Nor can it act as a strategic asset in the way that Serum Institute of India has been for India. South Africa has about one twentieth the population of India. This means it will need its public vaccine production capacity to grow to a more modest size to be a strategic asset.The Conversation

Jeffrey Dorfman, associate professor in Medical Virology, Stellenbosch University and Frank Kirstein, Honorary Research Associate / Lecturer; Division of Immunology, Faculty of Health Sciences, University of Cape Town

This article is republished from The Conversation under a Creative Commons licence. Read the original article.

COMMENTS   22

Sort by:
  • Oldest first
  • Newest first
  • Top voted

You must be signed in to comment.

SIGN IN SIGN UP

The vaccines have been shown to be far less effective than expected and often with serious side effects.

Ivermectin has been in use for decades and has been shown to be safe.

Ivermectin is cheaper than vaccines, and will only be required when a person is sick as opposed to having a frequent jab that is a nice regular income stream for pharma companies that are clearly lobbying politicians to get their “wunderdrugs” into the economy.

Really a no-brainer for SA politicians. Even if they have no brains, they should be able to see that approving Ivermectin will have far better outcomes economically due to manageable health, and the ability to mass produce it right here in SA at Aspen.

WTF

Ivermectin does not work against the corona virus. It was a small study that reported that it worked but further larger studies reported that it does not. What’s next? hydrochloroquine??
The dangers of misinterpreting medical findings.

Where is the vaccine?

The dangers of obtaining a PhD from google without a single peer assessed dissertation in sight.
Khande, Thank you for your insightful comment.

@Kande The clinical evidence in the public domain says otherwise. Ivermectin is a very safe drug and has been in use for several decades.

Hydrochloroquine has a significant risk of serious side effects.

Several medical specialists in South Africa are trying to get government to approve Ivermectin for use. It is used elsewhere in the world.

Interestingly, even the vaccines that have been released so far have high risk of serious side effects include allergic reactions that require medical intervention to survive.

Great comment. I find the comments on MW very helpful in providing the full picture.

worked for decades…against Cov19?…how do you know?..any tests available?…. I am not saying that it might not work but lets wait for tests before we can make statements like this. Side effects…you can go blind.

@DeonK It has been in use for decades and has been shown to be safe. It has recently been used in Covid19 cases and thus far has shown signficant benefit.

We want as much people as possible to take the vaccine , in order to achieve herd immunity. That’s the only way we can beat covid.

Luckily herd immunity didn’t require 100% immunity, let’s try and get as many people as possible to take the vaccine , so we don’t have to…

Just call the Israelis and beg them for help. All is forgiven.
They have vaccinated (1st dose ) 40% of their population in 5 weeks. This is also the more vulnerable population( ie middle aged and elderly). Once the second dose is done and a week or two passes just watch their death rate plummet.

No wonder they have won every war they have fought( and they have had many)

Although Israel is the panacea for its neighboring countries’ deficiencies, it has however NOT won every war it has been in.

Furthermore and hundreds of years later,
There was a particular religious war that took place in Israel where the Jews were the absolute minority (as they have been mercilessly killed) and by far out-matched and out-powered…in their own country, by the foreign Christians and Muslims as each religion fought for its own dominance and rule.

yeah right…that’s why more noble prizes on medicine and science have been bagged by Jews

I’ll be happy to have a jab from a Jewish outfit

Leah Buchanan

I was merely correcting Sam The Taxman on Israel and its record on war. I mentioned NOTHING about their efforts in vaccinating its citizens, so please do not bring that shade towards me in that manner! I am not a political conduit for divisive purposes. Clean your tone when you wish to engage with me further, so that we can engage with one another in an intellectual precedent… where we talk around real, factual and concrete events from history.

Incorrect Kind Khan! Israel was only formed in 1948 and they have beaten the hell out of their enemies often on numerous simultaneous fronts. I fondly remember Brezhnev threatening and begging Kissinger to stop annihilating the Egyptian 3rd army after Israeli forces surrounded them in 1973.

Sam The Taxman

Good Sir, I thank you for making the distinction between the archaic Jewish religious landmass and the actual Jewish State(Israel). As per your preceding commentary, you are absolutely correct and i humbly thank you for the enlightenment.

Be well.

SA may have the “capacity”, but unlike to have the “ability”.

(let’s not rule out labour strikes either)

Let’s rather leave production to countries like India.

Step 1 : Restore reliable electricity supply.

Step 2 : The rest.

What happened to the vaccine unit at Onderstepoort? SA produced animal vaccines in the past. Surely this expertise is still around?

Pharmaceutical companies making billions with a placebo product !

End of comments.

LATEST CURRENCIES  

USD / ZAR
GBP / ZAR
EUR / ZAR

Podcasts

INSIDER SUBSCRIPTIONS APP VIDEOS RADIO / PODCASTS SHOP OFFERS WEBINARS NEWSLETTERS TRENDING PORTFOLIO TOOL CPD HUB

Follow us:

Search Articles: Advanced Search
Click a Company: